30 years of global pharma leadership · Former Novartis Executive · Chair, MAAA · Faculty Partner, ADEN · Basel & International
The most consequential challenges in healthcare governance rarely fit inside a single discipline. These six pillars represent the intersections where strategy, policy, evidence, and leadership must work together.
Boards that govern well create durable value; boards that react merely manage crises. This pillar examines how healthcare and life sciences boards can build accountability structures, manage regulatory risk, and exercise genuine strategic oversight.
Pharmaceutical pricing has moved from a commercial function to a board-level governance issue. This pillar addresses value-based access frameworks, reference pricing, and the policy forces reshaping what patients — and payers — ultimately pay.
Sustainable health systems are designed with intention, not inherited by default. This pillar explores system-level policy design, affordability frameworks, and the structural barriers that determine whether patients receive the treatments they need.
Artificial intelligence is already reshaping pharmaceutical development and health-system operations — yet most boards lack the frameworks to govern it responsibly. This pillar offers a governance lens on digital health transformation: oversight first, adoption second.
Evidence without application changes nothing. As Faculty Partner at ADEN Business School, I connect pricing strategy, market access, and health-system design to the decisions executives and policymakers must make today.
The Medicines Affordability & Adherence Alliance (MAAA) was founded on one conviction: that structural barriers — excessive margins, medication taxes, inadequate coverage — cost lives, not just money. As Founding President and Chair, I lead the Alliance's research, advocacy, and governance from Basel.